贝伐珠单抗治疗脑胶质瘤及放射性脑坏死

doi:10.3760/cma.j.issn.1673-422X.2014.01.009

摘要/Abstract

摘要： 贝伐珠单抗作为全球第一个抗血管生成的单克隆抗体，获得美国食品和药物管理局批准用于胶质母细胞瘤的挽救治疗，之后贝伐珠单抗治疗恶性胶质瘤成为研究的焦点，但最新研究结果并不支持其在恶性胶质瘤的一线治疗中应用。另外，该药在放射性脑坏死的治疗上也取得令人鼓舞的效果，确切疗效有待进一步证实。

关键词: 神经胶质瘤, 辐射损伤, 脑, 贝伐珠单抗

Abstract: The U.S. Food and Drug Administration approves bevacizumab for salvage therapy of glioblastoma in 2009, which is the first monoclonal antibody of antiangiogenesis in the global. Afterwards, bevacizumab for malignant glioma becomes the focus of research, but the latest studies do not support its use for the firstline treatment of malignant glioma. Furthermore, bevacizumab shows a encouraging effect for radiation encephalic necrosis and its final outcome remains to be further confirmed.

Key words: Glioma, Radiation injuries, Brain, Bevacizumab

潘雪峰, 邢红雨, 郑国宝. 贝伐珠单抗治疗脑胶质瘤及放射性脑坏死[J]. 国际肿瘤学杂志, 2014, 41(1): 27-30.

Pan Xuefeng, Xing Hongyu, Zheng Guobao. Bevacizumab for glioma and radiation encephalic necrosis[J]. Journal of International Oncology, 2014, 41(1): 27-30.

参考文献

［1］ Kerbel RS. Tumor angiogenesis［J］. New Engl J Med, 2008, 358(19):20392049. ［2］ Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors［J］. Curr Oncol Rep, 2010, 12(2):102108. ［3］ Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5year analysis of the EORTCNCIC trial［J］. Lancet Oncol, 2009, 10(5):459466. ［4］ Pichler J, Marosi C. Drug therapy of patients with recurrent glioblastoma: is there any evidence?［J］. Wien Med Wochenschr, 2011, 161(12):2631. ［5］ Onishi M, Ichikawa T, Kurozumi K, et al. Angiogenesis and invasion in glioma［J］. Brain Tumor Pathol, 2011, 28(1):1324. ［6］ Maiuri F, Del Basso De Caro M, Siciliano A, et al. Expression of growth factors in brain tumors: correlation with tumor grade,recurrence and survival［J］. Clin Neuropathol, 2010, 29(2):109114. ［7］ Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme［J］. J Clin Oncol, 2007, 25(30):47224729. ［8］ Desjardins A, Reardon DA, Herndon JE 2nd. et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas［J］. Clin Cancer Res, 2008, 14(21):70687073. ［9］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5):740745. ［10］ Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(28):47334740. ［11］ Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma［J］. Cancer, 2012, 118(5):13021312. ［12］ Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy［J］. Cancer, 2011, 117(23):53515358. ［13］ Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5):20182024. ［14］ Taal W, Oosterkamp HM, Walenkamp A ME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study［J］. J Clin Oncol, 2013, 31 Suppl:2001. ［15］ Lai A, Tran A, Nghiemphu PL, et al. Phase Ⅱ study of bevaeizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme［J］. J Clin Oncol, 2011, 29(2):142148. ［16］ Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase Ⅲ doubleblind placebocontrolled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)［J］. J Clin Oncol, 2013, 31 Suppl:1. ［17］ Henriksson R, Bottomley A, Mason W, et al. Progressionfree survival (PFS) and healthrelated quality of life (HRQoL) in AVAglio, a phase Ⅲ study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)［J］. J Clin Oncol, 2013, 31 Suppl:2005. ［18］ Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMTnonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial［J］. J Clin Oncol, 2013, 31 Suppl:LBA2000. ［19］ Fink J, Born D, Chamberlain MC. Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors［J］. Curr Neurol Neurosci Rep, 2012, 12(3):276285. ［20］ Siu A, Wind JJ, Iorgulescu JB, et al. Radiation necrosis following treatment of high grade gliomaa review of the literature and current understanding［J］. Acta Neurochir(Wien), 2012, 154(2):191201. ［21］ Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain［J］. Int J Radiat Oncol Biol Phys, 2007, 67(2):323326. ［22］ Wong ET, Huberman M, Lu XQ, et al. Bevacizumab reverses cerebral radiation necrosis［J］. J Clin Oncol, 2008, 26(34):56495650. ［23］ Liu AK, Macy ME, Foreman NK, et al. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas［J］. Int J Radiat Oncol Biol Phys, 2009, 75(4):11481154. ［24］ Benoit A, Ducray F, CartalatCarel S, et al. Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis［J］. J Neurol, 2011, 258(2):328329. ［25］ Levin VA, Bidaut L, Hou P, et al. Randomized doubleblind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the central nervous system［J］. Int J Radiat Oncol Biol Phys, 2011, 79(5):14871495. ［26］ Keunen O, Johansson M, Oudin A, et al. AntiVEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma［J］. Proc Natl Acad Sci USA, 201l, 108(9):37493754. ［27］ de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab:radiographic and pathologic correlation in humans and mice［J］. Neuro Oncol, 2010, 12(3):233242. ［28］ Furuse M, Kawabata S, Kuroiwa T, et al. Repeated treatment with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases［J］. J Neurooncol, 2011, 102(3):471475.

[1]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[2]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[3]	谢宇, 蒋澄, 黄明敏, 郭爱斌, 尹震宇, 林永娟. 超声测量视神经鞘直径评估鞘内灌注化疗对非小细胞肺癌软脑膜转移患者颅内压的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 532-539.
[4]	赵永瑞, 高莹, 陈怡东, 徐建堃. 基于直线加速器的分次立体定向放疗对小体积脑转移瘤的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 138-143.
[5]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[6]	谢宇, 郑胜男, 黄明敏, 郭爱斌, 尹震宇, 林永娟. 基于脑脊液药代动力学的培美曲塞应用于肺腺癌软脑膜转移患者鞘内注射化疗的临床研究[J]. 国际肿瘤学杂志, 2023, 50(10): 585-591.
[7]	林永娟, 李会颖, 尹震宇, 郭爱斌, 谢宇. 基于非靶标代谢组学的肺腺癌软脑膜转移患者脑脊液代谢特征研究[J]. 国际肿瘤学杂志, 2022, 49(7): 390-399.
[8]	费文静, 王文保, 谢欢欢, 闫婧, 杨觅. 胶质母细胞瘤相关小胶质细胞研究现状[J]. 国际肿瘤学杂志, 2022, 49(7): 420-424.
[9]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[10]	孙晓琳, 张展昱, 许林宗, 刘英超, 李晓梅. 放疗联合免疫治疗在乳腺癌脑转移瘤中的潜在价值[J]. 国际肿瘤学杂志, 2022, 49(4): 243-246.
[11]	纪环, 周菊英, 马辰莺, 徐晓婷, 秦颂兵. 非小细胞肺癌脑转移的放疗进展[J]. 国际肿瘤学杂志, 2022, 49(3): 181-184.
[12]	林榕生, 吴楚海, 郭颖梅, 王涛, 陈荣斌, 刘少琴, 甘兵. 特瑞普利单抗联合贝伐珠单抗二线以上治疗MSI-H型转移性结直肠癌的疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(2): 100-105.
[13]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[14]	卢丽娜, 宦坚. 纳武利尤单抗治疗胃癌致免疫性心肌炎继发免疫性脑炎1例[J]. 国际肿瘤学杂志, 2022, 49(10): 639-640.
[15]	张红娥, 周清华, 刘洁薇, 代爽, 周洁. 预防性全脑照射引起小细胞肺癌患者脑损伤的研究进展[J]. 国际肿瘤学杂志, 2021, 48(9): 568-571.